Benralizumab + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Gastritis or Gastroenteritis
Conditions
Eosinophilic Gastritis or Gastroenteritis
Trial Timeline
Apr 23, 2018 → Jan 12, 2022
NCT ID
NCT03473977About Benralizumab + Placebo
Benralizumab + Placebo is a phase 2/3 stage product being developed by AstraZeneca for Eosinophilic Gastritis or Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03473977. Target conditions include Eosinophilic Gastritis or Gastroenteritis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05692180 | Phase 3 | Recruiting |
| NCT05251909 | Phase 3 | Terminated |
| NCT04612790 | Phase 3 | Terminated |
| NCT04191304 | Phase 3 | Active |
| NCT04185012 | Phase 3 | Completed |
| NCT03953300 | Approved | Active |
| NCT04053634 | Phase 3 | Completed |
| NCT03470311 | Phase 3 | Completed |
| NCT03473977 | Phase 2/3 | Completed |
| NCT03186209 | Phase 3 | Completed |
| NCT02322775 | Phase 3 | Completed |
| NCT01947946 | Phase 3 | Terminated |
| NCT01928771 | Phase 3 | Completed |
| NCT01914757 | Phase 3 | Completed |
Competing Products
20 competing products in Eosinophilic Gastritis or Gastroenteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| benralizumab + benralizumab + Placebo | Kyowa Kirin | Phase 2 | 52 |
| SHR-1703 + SHR-1703 Placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Esomeprazole + Budesonide | AstraZeneca | Phase 2/3 | 65 |
| Tezepelumab + Tezepelumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Approved | 85 |
| Cohort | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Matching placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab Prefilled Syringe | AstraZeneca | Approved | 85 |
| benralizumab | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| inhaled/swallowed budesonide + viscous/swallowed budesonide | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + 129 Xenon | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |